Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.61 |
| ▸ | TK2 | O00142 | 2/20 | 0.59 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547183 | 0.88 | PYGM (0.60) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL8369203 | 0.85 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13518430 | 0.84 | PYGM (0.55) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL40820 | 0.84 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18503568 | 0.84 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512917 | 0.84 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512919 | 0.84 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL40819 | 0.84 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL23083301 | 0.83 | TK2 (0.74) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2587226 | 0.83 | TK2 (0.74) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023233-A2 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220088097-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2022-03-24 | — | — | US | claimed |
| EP-3518947-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018064134-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2018-04-05 | — | — | WO | claimed |
| US-20180085411-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2018-03-29 | — | — | US | claimed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | claimed |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-08-25 | — | — | US | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| US-6063628-A | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2000-05-16 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| US-20240052357-A1 | AUTONOMOUS INDUCIBLE DIRECTED EVOLUTION OF COMPLEX PATHWAYS | NORTH CAROLINA STATE UNIVERSITY | 2024-02-15 | — | — | US | disclosed |
| CN-117085047-A | Optimized oncolytic viruses and uses thereof | 萨特治疗学有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-3518947-B1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109982708-B | Optimized oncolytic viruses and uses thereof | 萨特治疗学有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | disclosed |
| US-6063628-A | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | PYGM 3753/4885TK2 279/4885SLC28A1 891/4885 |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | PYGM 3753/4885TK2 279/4885SLC28A1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.